
ProPhase Labs Announces Proposed Reverse Merger with ABL

I'm PortAI, I can summarize articles.
ProPhase Labs announced a proposed reverse merger with Advanced Biological Laboratories (ABL), making ABL the majority owner. This merger aims to align ProPhase with ABL's biotech focus, impacting its ownership structure and strategic direction. Analysts rate PRPH stock as Hold with a $0.13 target, citing weak financial performance and bearish technical indicators. ProPhase operates in healthcare and consumer products, focusing on diagnostic testing and consumer health products.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

